Thrombolex Inc.

Founded in 2016, Thrombolex, Inc. is engaged in the design, development, manufacture and distribution of innovative endovascular catheters.

05/01/2026

Efficiency in PE intervention is about structure and consistency.

The BASHIR® Endovascular Device is designed with efficiency in mind, integrating mechanical clot engagement with targeted thrombolytic delivery during on-the-table (OTT) pharmaco-mechanical lysis (PML). This coordinated approach supports a safe streamlined interventional procedure.

See how workflow is supported at Thrombolex.com.

04/30/2026

Pulmonary embolism intervention demands focus at every step.

The BASHIR® Endovascular Device is designed to deliver a safe, on-the-table (OTT) pharmaco-mechanical lysis (PML) procedure by integrating mechanical clot fragmentation with targeted thrombolytic delivery. This coordinated approach helps maintain procedural flow and consistency during PE treatment, supporting a structured and efficient intervention from start to finish.

Thrombolex.com

04/29/2026

Thank you to SCAI 2026 and the Interventional Cardiology community for an outstanding event.

It was a pleasure connecting and continuing important conversations around pulmonary embolism intervention, targeted pharmaco-mechanical lysis (PML), and clinical practice.

Thrombolex.com

04/28/2026

Thrombolex’s Clinical Library provides an in-depth resource of physician-focused videos, case materials, and procedural insights that illustrate how the BASHIR® Family of Endovascular Devices are used in real clinical settings. These materials are designed to support safe, efficient application of targeted, thrombolytic delivery combined with mechanical clot fragmentation and to reinforce procedural confidence and best practices in PE intervention and other thromboembolic conditions.

Visit the Clinical Library to deepen your understanding of endovascular approaches in everyday practice.

Thrombolex.com

04/27/2026

Clinical evidence plays a critical role in PE care. Interim data from the RAPID-PE Study showed that all 50 patients met the primary endpoint, no PE related deaths and no cardio pulmonary decompensation. Confidence when it matters most.

Thrombolex.com

04/26/2026

Precision is not optional in PE care.

By integrating mechanical clot fragmentation with targeted thrombolytic delivery, the BASHIR® Endovascular Device supports a focused approach to intervention. This balance helps clinicians treat PE with confidence, delivering therapy where it is needed while maintaining procedural consistency and control.

Thrombolex.com

04/25/2026

Not all PE interventions rely on the same approach.

The BASHIR® Endovascular Device integrates mechanical clot fragmentation with targeted thrombolytic delivery, improving the safety profile for PE treatment. By combining localized pharmacologic therapy with mechanical interaction, this integrated approach supports focused exposure and structured clot modification during on-the-table (OTT) pharmaco-mechanical lysis (PML).

Thrombolex.com

04/23/2026

The SCAI 2026 Scientific Sessions begin today in Montréal, Canada.

Join Thrombolex at Booth 720 to connect with the Interventional Cardiology community and learn more about pulmonary embolism intervention using the BASHIR® Endovascular Device and targeted pharmaco-mechanical lysis (PML).

Thrombolex.com

04/22/2026

Thrombolex is proud to support the SCAI Workshop on the Treatment of Pulmonary Embolism: PERT Frameworks, Guideline Updates, and Procedural Skills.

Join us tomorrow at the Hands-on Learning Lab with Endovascular PE Devices. Connect with our team and get hands-on experience with the BASHIR® Endovascular Device and targeted pharmaco-mechanical lysis (PML) in PE intervention.

Thrombolex.com

04/21/2026

In PE treatment, delivery makes the difference.

The BASHIR® Endovascular Device is designed to mechanically fragment the clot while delivering thrombolytics in a targeted manner, helping clinicians balance effectiveness with controlled exposure.

Thrombolex.com

04/18/2026

The RAPID-PE Study evaluates the on-the-table protocol using pharmaco-mechanical lysis (PML) with the BASHIR® Endovascular Catheter. This post-market study focuses on safety, feasibility, and effectiveness in clinical practice, supporting confidence in targeted PE treatment.

Visit our website to learn more about the RAPID-PE study.

Thrombolex.com

04/17/2026

Thrombolex will be attending the SCAI 2026 Scientific Sessions. We look forward to connecting with the interventional cardiology community and continuing conversations around pulmonary embolism intervention, targeted thrombolytic delivery, and procedural approaches that support clinical confidence in PE care.

Thrombolex.com

Address

75 Britain Drive
New Britain, PA
18901

Telephone

+18447926300

Website

http://www.thrombolex.com/

Alerts

Be the first to know and let us send you an email when Thrombolex Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Thrombolex Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in New Britain?